Association Between Thromboelastography and Coronary Heart Disease

Abstract

Background Thromboelastography (TEG) is a novel blood viscoelasticity detection method revealing blood coagulation status and has been reported to be helpful in predicting clinical outcomes in patients with cardiovascular diseases (CVD). In this study, we aimed to investigate the association between TEG and CVD. Material/Methods A single-center case-control study was performed. Individuals who took TEG tests at Tongji Hospital in Wuhan, China from 2015 to 2019 were included. The nearest-neighbor Mahalanobis matching with replacement, within propensity score calipers of 0.25 was used to control the covariate imbalance between CVD patients and controls. Logistic regression analyses were conducted to assess the relationship between TEG and CVD. Subgroup and sensitivity analyses were performed to evaluate the robustness of the association between TEG and CVD. Results After matching, a total of 151 participants were included in this study, with 83 patients having CVD (49 patients having coronary heart disease [CHD] and 34 patients having an ischemic stroke). By comparison, CHD patients had a significantly higher maximum amplitude (MA) ( P =0.02) than controls. After multivariable adjustment, MA (OR 1.11, 95% CI 1.01–1.24, P =0.04) was independently associated with CHD. The association between MA and CHD remained robust across subgroups and in sensitivity analyses. Conclusions The current study suggests that MA is significantly associated with CHD. Enhanced platelet reactivity as described by high MA might be associated with risk of CHD. The exact role of MA in the measurement of CHD risk needs to be further examined in large-scale prospective cohort studies.

The effect of Mycobacterium tuberculosis treatment on thrombelastography-assessed haemostasis: a prospective cohort study

“…CK MA has previously been used as the primary TEG outcome parameter for CVD risk assessment [28][29][30][31][32][33][34][35][36][37].…”

“…CK MA has previously been used as the primary TEG outcome parameter for CVD risk assessment [ 28 – 37 ]. Studies comparing CK MA in individuals with high vs. low CVD risk have shown similar differences as those observed in this present study.…”

“…Thrombelastography (TEG) is widely used to monitor and direct haemostatic treatment and captures the different aspects of haemostasis from clot initiation to clot lysis [28]. In recent years, it has been demonstrated that TEG can detect prothrombotic haemostatic alterations in populations with high CVD risk compared to controls and may be a useful tool for predicting CVD risk [28][29][30][31][32][33][34][35][36][37].…”

Deciphering correlation and causation in risk factors for heart disease with Mendelian randomization

“…Coronary artery disease (CAD), a condition caused by the buildup of plaque in the wall of the arteries that supply blood to the heart, is the leading cause of death for men and women in the United States (1). Nearly 610,000 Americans and 17.8 million people worldwide die annually from heart disease (2,3).…”